Evolving Treatment Paradigms in Advanced Renal Cell Carcinoma

Video

Hans Hammers, MD, PhD, discusses the evolving treatment paradigms in patients with advanced renal cell carcinoma and how recent clinical trial data may optimize future treatment selections.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      2 experts in this video
      The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape
      2 experts in this video
      Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
      Study Reveals Stark Disparities in RCC Clinical Trial Access Worldwide
      Study Reveals Stark Disparities in RCC Clinical Trial Access Worldwide
      Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
      Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
      2 experts in this video
      Lenvatinib in Advanced HCC: Considerations for Monotherapy and Combination Regimens
      2 experts in this video
      First-Line Therapy for Advanced HCC: The Role of TKIs and ICIs
      2 experts in this video
      Considerations for Treatment Approaches in Intermediate-Stage HCC
      2 experts in this video
      Navigating the Evolving First-Line Treatment Regimens in Intermediate-Stage HCC
      1 expert in this video
      Navigating TKI Toxicities: Expert Perspectives and Clinical Distinctions
      2 experts in this video
      When to Move Beyond TACE: The Expanding Role of Systemic Therapy in Intermediate-Stage HCC
      Related Content
      Participants Explain Rationale for Different IO/TKI Options for ccRCC

      Participants Explain Rationale for Different IO/TKI Options for ccRCC

      Targeted Oncology Staff
      April 15th 2025
      Article

      During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.

      Read More

      Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

      Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

      Jordyn Sava;Peter Zang, MD
      March 1st 2024
      Podcast

      In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

      Listen

      Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

      Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

      Targeted Oncology Staff
      April 10th 2025
      Article

      During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after immune checkpoint inhibitors.

      Read More

      Beyond the First-Line: Economides on Advancing Therapies in RCC

      Beyond the First-Line: Economides on Advancing Therapies in RCC

      Jordyn Sava;Minas P. Economides, MD
      February 1st 2024
      Podcast

      In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

      Listen

      Reviewing RCC Treatment Choices After Progression With IO/TKI

      Reviewing RCC Treatment Choices After Progression With IO/TKI

      Targeted Oncology Staff
      March 27th 2025
      Article

      During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.

      Read More

      Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC

      Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC

      Targeted Oncology Staff
      March 11th 2025
      Article

      During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.

      Read More